Trial Details

COMPLETED
Basic Information
Clinical ID c718
Identifier NCT05706038
Trial Title Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Inflammatory Bowel Diseases|Rheumatic Disorder
Interventions DRUG: Adalimumab
Participant Information
Sponsor IRCCS San Raffaele
City Milano
Country/Region Italy
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase -
Time Information
Start Date 2022-04-27
Primary Completion Date 2022-10-31
Completion Date 2022-10-31